BiomX Inc.(PHGE)

POST0.60990.03+4.29%18:37 EDT

0.5848-0.0452-7.17%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- BiomX FY 2024 GAAP EPS $(3.36) Misses $(2.56) Estimate, BiomX's Cash Balance And Restricted Cash As Of December 31, 2024 Were $18M, Excluding The Additional $12M In Gross Proceeds Raised In The Company's February 2025 Financing Round. BiomX Estimates Its Cash, Cash Equivalents And Short-term Deposits Are Sufficient To Fund Its Operations Into Q1 Of 2026
  Benzinga · 03-25 10:33
  BiomX FY 2024 GAAP EPS $(3.36) Misses $(2.56) Estimate, BiomX's Cash Balance And Restricted Cash As Of December 31, 2024 Were $18M, Excluding The Additional $12M In Gross Proceeds Raised In The Company's February 2025 Financing Round. BiomX Estimates Its Cash, Cash Equivalents And Short-term Deposits Are Sufficient To Fund Its Operations Into Q1 Of 2026
- BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates
  GlobeNewswire · 03-25 10:30
  BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates
- Biomx to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
  THOMSON REUTERS · 03-19
  Biomx to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
- BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
  GlobeNewswire · 03-19
  BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
- Biomx Inc - Topline Results From Phase 2B Study Expected in Q1 2026
  THOMSON REUTERS · 02-26
  Biomx Inc - Topline Results From Phase 2B Study Expected in Q1 2026
- Biomx Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million
  THOMSON REUTERS · 02-26
  Biomx Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million
- Biomx Inc - Proceeds to Support Phase 2B Study of Bx004 for Cystic Fibrosis
  THOMSON REUTERS · 02-26
  Biomx Inc - Proceeds to Support Phase 2B Study of Bx004 for Cystic Fibrosis
- Press Release: BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million
  Dow Jones · 02-26
  Press Release: BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million
- BiomX Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
  Dow Jones · 01-10
  BiomX Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
- BiomX regains compliance with NYSE American continued listing standards
  TIPRANKS · 2024-12-16
  BiomX regains compliance with NYSE American continued listing standards
- Biomx Inc. Receives Notice of Compliance With Nyse American Continued Listing Standards
  THOMSON REUTERS · 2024-12-16
  Biomx Inc. Receives Notice of Compliance With Nyse American Continued Listing Standards
- BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards
  GlobeNewswire · 2024-12-16
  BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards
- BiomX Q3 EPS $(0.31) Up From $(1.30) YoY; Cash Balance $24.7M
  Benzinga · 2024-11-14
  BiomX Q3 EPS $(0.31) Up From $(1.30) YoY; Cash Balance $24.7M
- Biomx Inc: Qtrly Share Loss $0.31
  THOMSON REUTERS · 2024-11-14
  Biomx Inc: Qtrly Share Loss $0.31
- Press Release: BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
  Dow Jones · 2024-11-14
  Press Release: BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
- BiomX announces mandatory unit separation
  TipRanks · 2024-10-16
  BiomX announces mandatory unit separation
- Biomx Inc - Warrants Will Expire on October 28
  THOMSON REUTERS · 2024-10-15
  Biomx Inc - Warrants Will Expire on October 28
- Biomx-Each Warrant Entitles Holder to Purchase One-Half of a Share of Common Stock at $115 per Share
  THOMSON REUTERS · 2024-10-15
  Biomx-Each Warrant Entitles Holder to Purchase One-Half of a Share of Common Stock at $115 per Share
- Biomx Announces a Mandatory Unit Separation
  THOMSON REUTERS · 2024-10-15
  Biomx Announces a Mandatory Unit Separation
- BiomX Announces a Mandatory Unit Separation
  GlobeNewswire · 2024-10-15
  BiomX Announces a Mandatory Unit Separation
Company Profile
Company Name
BiomX Inc.
Market
AMEX
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.biomx.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
- 03-25 04:00
  Annual Report
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 03-25 04:00
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 03-05
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 02-27
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-12-16
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-11-14
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2024-11-14
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-11-13
  Beneficial Ownership Change
  Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 2024-11-04
  Beneficial Ownership Change
  Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 2024-10-28
  Beneficial Ownership Change
  Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 2024-10-25
  Delisting
  Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
  Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
- 2024-10-15
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-09-26
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2024-09-12
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2024-08-16
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report

1D
5D
Day
Week
Month

Loading ...

High

0.6200

Open

0.6101

Volume%

1.41

Low

0.5700

0.6300

T/O Rate

0.48%

抱歉，当前请求异常(-1)

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

BiomX Inc.(PHGE)

Company Profile